
浏览全部资源
扫码关注微信
1.中国中医科学院 西苑医院,北京 100091
2.山西省中医药研究院,太原 030012
3.中国中医科学院,北京 100700
4.广州中医药大学 第二附属医院,广州 510120
马祥雪,博士,主治医师,从事功能性胃肠病中医药防治研究,Tel:010-62835641,E-mail:maxiangxue@163.com
* 唐旭东,博士,教授,首席研究员,主任医师,从事中西医结合功能性胃肠病基础与临床研究,E-mail:txdly@sina.com
收稿日期:2020-04-06,
网络出版日期:2020-08-25,
纸质出版日期:2020-11-05
移动端阅览
马祥雪,吉海杰,吕林等.肠安Ⅰ号方含药血清对致敏肥大细胞活化脱颗粒的影响[J].中国实验方剂学杂志,2020,26(21):48-54.
MA Xiang-xue,JI Hai-jie,LYU Lin,et al.Effect of Medicated Serum Prepared with Chang'an Ⅰ Prescription on Sensitized Mast Cell Degranulation[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(21):48-54.
马祥雪,吉海杰,吕林等.肠安Ⅰ号方含药血清对致敏肥大细胞活化脱颗粒的影响[J].中国实验方剂学杂志,2020,26(21):48-54. DOI: 10.13422/j.cnki.syfjx.20202136.
MA Xiang-xue,JI Hai-jie,LYU Lin,et al.Effect of Medicated Serum Prepared with Chang'an Ⅰ Prescription on Sensitized Mast Cell Degranulation[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(21):48-54. DOI: 10.13422/j.cnki.syfjx.20202136.
目的
2
探讨肠安Ⅰ号方含药血清对免疫球蛋白E(IgE)介导的大鼠嗜碱性粒细胞(RBL-2H3)活化脱颗粒的影响及对非受体型酪氨酸蛋白激酶/脾酪氨酸蛋白激酶/丝裂原活化蛋白激酶(Lyn/Syk/MAPK)信号通路的调节作用。
方法
2
制备肠安Ⅰ号方含药血清,将SD雄性大鼠随机分为肠安Ⅰ号方高、中、低剂量组及空白组,每组10只,给药剂量:空白组给予10 mL·kg
-1
蒸馏水灌胃,肠安Ⅰ号方低、中、高剂量组分别予1.15,2.30,4.60 g·kg
-1
药液灌胃,给药体积10 mL·kg
-1
,1次/d,连续灌胃7 d。细胞分组:空白组,予正常大鼠血清;模型组,予正常大鼠血清;酮替芬组,予正常大鼠血清+30 μmol·L
-1
酮替芬。肠安Ⅰ号方低、中、高剂量组分别为予肠安Ⅰ号方低、中、高剂量含药血清。建立IgE介导的RBL-2H3细胞活化、脱颗粒模型,采用甲苯胺蓝染色进行肥大细胞计数;采用比色法检测细胞脱颗粒
β
-氨基己糖释放率;采用酶联免疫吸附测定(ELISA)检测细胞上清中肥大细胞类胰蛋白酶(MCT),肿瘤坏死因子-
α
(TNF-
α
),单核细胞趋化蛋白-1(MCP-1)及组胺含量;采用蛋白免疫印迹法(Western blot)检测Lyn/Syk/MAPK通路蛋白表达。
结果
2
对于细胞活化脱颗粒,与空白组比较,模型组细胞
β
-氨基己糖释放率显著升高(
P
<
0.01),脱颗粒率明显升高(
P
<
0.05);与模型组比较,肠安Ⅰ号方含药血清各剂量组细胞
β
-氨基己糖释放率显著下降(
P
<
0.01),细胞脱颗粒率明显下降(
P
<
0.05)。对于活性介质释放,与空白组比较,模型组细胞上清组胺,MCT,TNF-
α
及MCP-1含量均显著增高(
P
<
0.01);与模型组比较,肠安Ⅰ号方各剂量组细胞上清组胺,MCT,TNF-
α
及MCP-1含量均显著减低(
P
<
0.01)。与正常组比较,模型组细胞Lyn和Syk及细胞外调节蛋白激酶1/2(ERK1/2),c-Jun氨基末端激酶(JNK),p38 MAPK磷酸化水平明显升高(
P
<
0.05);与模型组比较,肠安Ⅰ号方各剂量Lyn,Syk及ERK1/2,JNK及p38蛋白磷酸化水平明显降低(
P
<
0.05)。
结论
2
肠安Ⅰ号方含药血清通过下调RBL-2H3细胞活化上游信号通路关键蛋白Lyn,Syk和下游ERK1/2,JNK及p38蛋白的磷酸化水平,抑制肥大细胞活化脱颗粒,减少组胺,MCT,TNF-
α
及MCP-1等活性介质释放,这可能是其抑制肥大细胞活化,治疗腹泻型肠易激综合征(IBS-D)内脏高敏感的机制之一。
Objective
2
To observe the influence of Chang'an Ⅰ prescription drug-containing serum on IgE-mediated RBL-2H3 cell degranulation model, and explore the mechanism of Chang'an Ⅰ prescription in inhibiting RBL-2H3 activation degranulation and releasing inflammatory mediators with v-yes-1 Yanaguchi sarcoma viral related oncogene homolog (Lyn)/spleen tyrosine protein kinase (Syk)/mitogen-activated protein kinase (MAPK) signal pathway.
Method
2
Preparation for Chang'an Ⅰ prescription serum. Animal group, SD male rats were randomly divided into Chang'an Ⅰ prescription serum high, medium, low dose, and blank control groups with 10 rats in each group. Dosage: 10 mL·kg
-1
distilled water was given to blank control group, while Chang'an Ⅰ prescription serum high, medium and low dose groups were respectively given to the Chang'an Ⅰ prescription concentrated crude drug with concentration of 1.15,2.30,4.60 g·kg
-1
, respectively once a day for 7 days continuously and then blood was taken from aorta ventralis and centrifuged. Ketotifen as the positive control drug. Mast cells are counted with toluidine blue staining. Cellular release of
β
-aminohexose was detected by colorimetric method. Contents of MCT, TNF-
α
, MCP-1 and histamine were measured by enzyme-linked immunosorbent assay (ELISA) kits, Lyn/Syk/MAPK protein levels were detected by immunoblotting.
Result
2
For cell activation and degranulation, compared with the blank control group, the model group had more cell degranulation (
P
<
0.05), compared with model group, the cell degranulation rate of each dose group of Chang'an Ⅰ prescription decreased (
P
<
0.05). The release rate of
β
-hexosamine in each dose group of Chang'an Ⅰ prescription decreased significantly (
P
<
0.01). For the release of active mediators, compared with the blank control group, the contents of histamine, MCT, TNF-
α
and MCP-1 all increased in the model group (
P
<
0.01), compared with the model group, the contents in each dose group of Chang'an Ⅰ prescription all decreased significantly (
P
<
0.01). Compared with the normal group, the phosphorylation levels of Lyn and Syk, extracellular regulatory protein kinase 1/2(ERK1/2), c-Jun N-terminal kinase (JNK), and mitogen-activated protein kinase p38 increased in the model group (
P
<
0.05). Compared with the model group, the Lyn, Syk and ERK1/2, JNK and p38 protein phosphorylation levels reduced in Chang'an Ⅰ prescription group (
P
<
0.05).
Conclusion
2
Chang'an Ⅰ prescription drug-containing serum down-regulates the phosphorylation levels of proteins Lyn, Syk, and ERK1/2, JNK, and p38, inhibits RBL-2H3 cell activation and degranulation, reduces the release of cytokines and chemokines, such as histamine, MCT, TNF-
α
and MCP-1, it may be one of its mechanisms for treating IBS-D visceral hypersensitivity.
PIMENTEL M . Evidence-based management of irritable bowel syndrome with diarrhea [J]. Am J Manag Care , 2018 , 24 ( 3 /l): S35 - S46 .
SPERBER A D , BANGDIWALA S I , DROSSMAN D A , et al . Worldwide prevalence and burden of functional gastrointestinal disorders,results of rome foundation global study [J]. Gastroenterology , 2020 , 16 ( 20 ): 30487 .
SCHOENFELD P S . Advances in IBS 2016:a review of current and emerging data [J]. Gastroenterol Hepatol , 2016 , 12 ( 8/3 ): 1 - 11 .
BI Z , ZHENG Y , YUAN J , et al . The efficacy and potential mechanisms of Chinese herbal medicine on irritable bowel syndrome [J]. Curr Pharm Des , 2017 , 23 ( 34 ): 5163 - 5172 .
LIU J P , YANG M , LIU Y X , et al . Herbal medicines for treatment of irritable bowel syndrome.Cochrane Db Syst Rev [J]. 2006 , doi: 10.1002/14651858.CD004116.pub2 http://dx.doi.org/10.1002/14651858.CD004116.pub2 .
张伟 , 孙建华 , 裴丽霞 , 等 . 中医药治疗肠易激综合征的系统评价/Meta分析的再评价 [J]. 世界华人消化杂志 , 2014 , 22 ( 12 ): 1747 - 1755 .
刘慧 , 刘力 , 王捷虹 . 中医疏肝健脾法治疗腹泻型肠易激综合征的Meta分析 [J]. 现代中医药 , 2019 , 39 ( 4 ): 81 - 84,95 .
唐旭东 . 一种治疗肠易激综合征的中药组合物及其制备方法 : 中国 , CN103845702A [P]. 2014-06-11 .
TANG X D , LV B , LI Z H , et al . Therapeutic effect of Chang'an I recipe (I) on irritable bowel syndrome with diarrhea:a multicenter randomized double-blind placebo-controlled clinical trial [J]. Chin J Integr Med , 2018 , 24 ( 9 ): 645 - 652 .
马祥雪 . 肥大细胞活化在IBS-D内脏高敏感中的作用及肠安Ⅰ号方的干预研究 [D]. 北京 : 北京中医药大学 , 2017 .
徐叔云 , 卞如濂 , 陈修 . 药理实验方法学 [M]. 北京 : 人民卫生出版社 , 2002 : 202 - 203 .
CATANZARO R , OCCHIPINTI S , CALABRESE F , et al . Irritable bowel syndrome:new findings in pathophysiological and therapeutic field [J]. Minerva Gastroenterol Dietol , 2014 , 60 ( 2 ) : 151 - 163 .
ZHANG L , SONG J , HOU X . Mast cells and irritable bowel syndrome:from the bench to the bedside [J]. J Neurogastroenterol Motil , 2016 , 22 ( 2 ) : 181 - 192 .
WOUTERS M M , VICARIO M , SANTOS J . The role of mast cells in functional GI disorders [J]. Gut , 2016 , 65 ( 1 ) : 155 - 168 .
LEE H , PARK J H , PARK D I , et al . Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome [J]. J Neurogastroenterol Motil , 2013 , 19 ( 2 ) : 244 - 250 .
MATSUDA H , NAKAMURA S , YOSHIKAWA M . Degranulation Inhibitors from medicinal plants in antigen-stimulated rat basophilic leukemia (RBL-2H3) cells [J]. Chem Pharm Bull , 2016 , 64 ( 2 ): 96 - 103 .
WERNERSSON S , PEJLER G . Mast cell secretory granules:armed for battle [J]. Nat Rev Immunol , 2014 , 14 ( 7 ) : 478 - 494 .
赵迎盼 , 苏敏 , 王凤云 , 等 . 肠安Ⅰ号方对肠易激综合征内脏高敏感大鼠5-HT信号系统及海马BDNF mRNA表达的影响 [J]. 中国中西医结合杂志 , 2015 , 35 ( 10 ): 1228 - 1235 .
0
浏览量
15
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621